← Leaderboards
Neil A Fanger
Virtici, Llc
$24,726,083
Attributed
$24,880,602
Total exposure
27
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,730,602 · 26
CDC$150,000 · 1
By mechanism
R44$12,137,780 · 6
R43$9,162,200 · 20
UT2$3,580,622 · 1
Top collaborators
- Cortney Halsey1 shared
Others in their field
Top investigators on “Small Business Innovation Research Grant”
- David Heimbrook · Leidos Biomedical Research, Inc.$122,677,088
- Praduman Jain · Vignet, Inc.$106,968,877
- Stephen Lev Hoffman · Sanaria, Inc.$37,771,680
- Eric Baer · Case Western Reserve University$37,136,000
- John B Buse · University Of North Carolina Chapel Hill$23,865,764
- Gary Fanger · Rise Therapeutics, Llc$23,463,293
Research focus
Small Business Innovation Research GrantAlzheimer&AposDoseDesignPreventPharmaceutical PreparationsSymptomsCellsToxicologyMedicalBaseBindingAffectMouse ModelOralInvestmentsFutureCommercializationAntibodiesChronicOral AdministrationPositioning AttributeInnovationAntigens
Grant awards (50)
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$999,989
R44 · FY2025 · HL · contact PI
A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection$698,684
R44 · FY2025 · DE · contact PI
A Novel Anti-infective Therapy for Treating Periodontitis$309,038
R43 · FY2025 · DE
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$1,049,994
R44 · FY2024 · HL · contact PI
A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection$923,623
R44 · FY2024 · DE · contact PI
A Novel Blood Test for Early Diagnosis of Frontotemporal Lobar Degeneration$700,000
R43 · FY2024 · NS · contact PI
A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection$306,500
R43 · FY2024 · AI · contact PI
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$978,755
R44 · FY2023 · AI · contact PI
A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection$306,500
R43 · FY2023 · AI · contact PI
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$306,492
R44 · FY2023 · HL · contact PI
A Novel Small Molecule for the Treatment of Periodontitis$306,391
R43 · FY2023 · DE · contact PI
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease$281,188
R43 · FY2023 · AG · contact PI
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease$257,417
R43 · FY2023 · AG · contact PI
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease$215,712
R43 · FY2023 · AG · contact PI
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$979,534
R44 · FY2022 · AI · contact PI
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease$441,280
R43 · FY2022 · AG · contact PI
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis$306,496
R44 · FY2022 · HL · contact PI
A Novel Small Molecule for the Treatment of Periodontitis$306,463
R43 · FY2022 · DE · contact PI
A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease$291,961
R43 · FY2022 · AG · contact PI
A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease$73,171
R43 · FY2022 · AG · contact PI
A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease$30,488
R43 · FY2022 · AG · contact PI
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$994,179
R44 · FY2021 · AI · contact PI
A Novel Multiparameter Blood Test for Early Detection of Alzheimer's Disease$412,462
R43 · FY2021 · AG · contact PI
A Novel LIGHT/TL1A Bispecific Antibody for the Treatment of Fibrotic Diseases$299,015
R43 · FY2021 · AI · contact PI
A Novel Probiotic-Based Nanobody Delivery Platform$281,113
R43 · FY2021 · AI · contact PI
ASCEND, Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain West IDeA States$1,374,707
UT2 · FY2020 · GM · contact PI
A Novel Probiotic-Based Nanobody Delivery Platform$300,000
R43 · FY2020 · AI · contact PI
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance$299,996
R44 · FY2020 · AI · contact PI
A Novel Therapeutic Peptide to Treat P. aeruginosa Infection in Cystic Fibrosis Patients$158,832
R43 · FY2020 · AI · contact PI
ASCEND, Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain West IDeA States$1,455,915
UT2 · FY2019 · GM · contact PI
A Novel Therapeutic Peptide to Treat P. aeruginosa Infection in Cystic Fibrosis Patients$299,836
R43 · FY2019 · AI · contact PI
ASCEND, Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain West IDeA States$250,000
UT2 · FY2019 · GM · contact PI
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis$990,104
R44 · FY2018 · AI · contact PI
A Novel Peptide Therapeutic for Obesity$829,401
R44 · FY2018 · DK · contact PI
ASCEND, Accelerating Solutions for Commercialization and Entrepreneurial Development in the Mountain West IDeA States$500,000
UT2 · FY2018 · GM · contact PI
A Novel Tolerance Therapeutic for Treating Graves' Disease$299,840
R44 · FY2018 · AI · contact PI
A Novel Peptide Therapeutic for Obesity$1,000,985
R44 · FY2017 · DK · contact PI
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis$1,000,000
R44 · FY2017 · AI · contact PI
A Novel Tolerance-inducing Probiotic Platform$300,000
R43 · FY2017 · AI · contact PI
A Novel Tolerance Therapeutic for Treating Type 1 Diabetes$300,000
R43 · FY2017 · DK · contact PI
A Novel Probiotic for the Treatment of Rheumatoid Arthritis$225,000
R43 · FY2017 · AR · contact PI
A Novel Tolerance Therapeutic for Treating Multiple Sclerosis$479,708
R44 · FY2016 · AI · contact PI
A Novel Probiotic for the Treatment of Sjogren's Syndrome$225,000
R43 · FY2016 · DE · contact PI
A Novel Therapeutic Peptide for Treating Stroke$434,135
R43 · FY2015 · NS · contact PI
A Novel Tolerance Therapeutic for Treating Peanut Allergy$318,728
R43 · FY2015 · AI · contact PI
XHA-A Novel Tolerance Therapeutic for Allergic Rhinitis$417,336
R43 · FY2014 · AI · contact PI
A Novel Peptide Therapeutic for Obesity$224,700
R43 · FY2014 · DK · contact PI
A Rapid, Blood RNA Assay for the Diagnosis of Acute Respiratory Infections$150,000
R43 · FY2013 · IP · contact PI
A Novel Tolerance Therapeutic to Treat Asthma$689,961
R43 · FY2012 · HL · contact PI
A Blood Test for Pre-symptomatic Detection of Sepsis$299,973
R43 · FY2012 · AI · contact PI